Fly News Breaks for October 11, 2019
Oct 11, 2019 | 06:25 EDT
Cantor Fitzgerald analyst Brian White upgraded GlaxoSmithKline to Buy from Hold with a price target of 2000 pence, up from 1450 pence. The Novartis transactions bolstered GSK's Vaccines and Consumer businesses at the expense of Pharma, while recent events have served to continue the theme while reinvigorating the cancer franchise, White tells investors in a research note. The analyst believes GSK has access to differentiated oncology products, "which promise to form a cornerstone for future franchise building." Further, consummation of the Consumer business should drive greater profitability "but Pharma has a narrow window to build a sustainable late stage pipeline," he adds.
News For GSK From the Last 2 Days